trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', 'daiichi', 'astrazeneca']
the ph ii enhertu data from astrazeneca &amp; daiichi sankyo pan-cancer her2 adc data is wow! 37% orr, ~40% excl. pdac. pdac continue to be a tough one. also fascinating to see the discrepancy between 2+ and 3+ score vs response in the biliary tract tumors. #asco23 
Senior Scientist at ArsenalBio Inc. ; Princess Margaret Cancer Centre alum. Sports Junkie.